Quidel Corporation Statement on President Trump’s Announcement of Coronavirus Testing Strategy

Nachrichtenquelle: Business Wire (engl.)
29.09.2020, 00:10  |  166   |   |   

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement supporting the Administration’s plans to provide COVID-19 rapid tests to school children.

“Quidel Corporation welcomes President Trump’s announcement that the Administration will direct millions of Abbott’s visually read antigen tests for use in safeguarding K-12 school children as they return to America’s classrooms. In this pandemic, the medical diagnostics industry is competing against COVID-19, not among companies. The need for testing seems virtually unlimited at this point in time. So, while Quidel continues our aggressive efforts to ramp production of our own rapid antigen tests, we appreciate the contributions of others and the leadership of the Trump Administration in clarifying how the special needs of school children will be addressed. Today’s announcement gives us greater certainty in confirming our commitments to existing customers and greater flexibility to serve additional markets as our production capacity expands.

“Quidel recently doubled our production of Sofia rapid antigen tests to the current rate of approximately two million tests per week. We are constructing additional production lines that will more than double our current capacity once again. Our goal is to reach a run-rate of over 220 million tests per year by July of 2021.

“We are proud of the commitment demonstrated by our Quidel team since the first day we started developing our PCR and antigen tests for COVID-19. Our people have been so dedicated and their ability to speed and scale production has been extraordinary. It is noteworthy that all of Quidel’s Sofia SARS Antigen test kits are made in America -- at our manufacturing facility near our corporate headquarters in San Diego.”

Background Information:

Quidel was the first company to receive EUA from the FDA for a rapid antigen test that delivers results in 15 minutes.

Sofia 2 is Quidel’s best-selling cartridge-based rapid diagnostic system for infectious disease testing, which utilizes fluorescent chemistry design, an intuitive graphical user interface, and optics system to provide a highly accurate, objective and automated result in 15 minutes. The Sofia 2 system also comes connected to Virena, Quidel’s data management system, which provides aggregated, de-identified testing data to public health authorities in near real-time.

Seite 1 von 3
Quidel Aktie jetzt ab 0€ handeln - auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel